Northwest Biotherapeutics, Inc. (NWBO)
0.1265
-0.01
(-8.99%)
USD |
OTCM |
Nov 20, 16:00
Northwest Biotherapeutics Enterprise Value : 308.73M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 308.73M |
| November 19, 2026 | 330.76M |
| November 18, 2026 | 341.51M |
| November 17, 2026 | 343.27M |
| November 16, 2026 | 343.45M |
| November 13, 2026 | 361.60M |
| November 12, 2026 | 376.75M |
| November 11, 2026 | 382.57M |
| November 10, 2026 | 379.75M |
| November 09, 2026 | 379.92M |
| November 06, 2026 | 379.18M |
| November 05, 2026 | 376.22M |
| November 04, 2026 | 376.58M |
| November 03, 2026 | 383.92M |
| November 02, 2026 | 395.78M |
| October 30, 2026 | 385.39M |
| October 29, 2026 | 382.74M |
| October 28, 2026 | 379.75M |
| October 27, 2026 | 370.41M |
| October 26, 2026 | 380.98M |
| October 23, 2026 | 353.14M |
| October 22, 2026 | 351.91M |
| October 21, 2026 | 383.10M |
| October 20, 2026 | 375.69M |
| October 19, 2026 | 359.18M |
| Date | Value |
|---|---|
| October 16, 2026 | 361.60M |
| October 15, 2026 | 358.53M |
| October 14, 2026 | 367.76M |
| October 13, 2026 | 372.15M |
| October 12, 2026 | 371.29M |
| October 09, 2026 | 362.48M |
| October 08, 2026 | 346.62M |
| October 07, 2026 | 347.50M |
| October 06, 2026 | 343.10M |
| October 05, 2026 | 348.03M |
| October 02, 2026 | 356.66M |
| October 01, 2026 | 354.37M |
| September 30, 2026 | 348.21M |
| September 29, 2026 | 322.46M |
| September 28, 2026 | 327.47M |
| September 25, 2026 | 339.99M |
| September 24, 2026 | 339.32M |
| September 23, 2026 | 339.40M |
| September 22, 2026 | 344.99M |
| September 21, 2026 | 351.67M |
| September 18, 2026 | 340.15M |
| September 17, 2026 | 349.17M |
| September 16, 2026 | 349.32M |
| September 15, 2026 | 360.19M |
| September 14, 2026 | 348.00M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.76M |
| Revenue (Quarterly) | 0.883M |
| Total Expenses (Quarterly) | 29.64M |
| EPS Diluted (Quarterly) | -0.017 |
| Gross Profit Margin (Quarterly) | -0.91% |
| Profit Margin (Quarterly) | -3.26K% |
| Earnings Yield | -19.13% |
| Normalized Earnings Yield | -25.30 |